Adoptive Transfer of Alloreactive Cells to Treat Patients With Poor-Prognosis Acute Myeloid Leukemia-01
The purpose of this study is to assess the safety and efficacy of infusing immune cells from
a donor as treatment for patients with acute myeloid leukemia that is resistant to
chemotherapy or who have experienced relapse. Unlike standard bone marrow or stem cell
transplantation which uses donors who are well 'matched' to the patient, this study uses
donors whose immune cells are not compatible with the patient. With standard stem cell or
bone marrow transplantation, the well-matched immune cells will attack the leukemia but they
also attack the patient's organs (a situation called graft-versus-host disease, which can
persist in the long term). Our hypothesis is that the mismatched donor cells will fight the
leukemia but will then be eliminated from the patient's body, so long-term side effects like
graft-versus-host disease should not occur.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society